Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Support Care Cancer. 2005 Oct;13(10):797-805. doi: 10.1007/s00520-005-0782-y. Epub 2005 Jul 16.
Support Care Cancer. 2005.
PMID: 16025262
Clinical Trial.
Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.
Kuhn W, Schmalfeldt B, Pache L, Späthe K, Ulm K, Renziehausen K, Nöschel H, Canzler E, Richter B, Kroner M, Tilch G, Janicke F, Graeff H.
Kuhn W, et al. Among authors: spathe k.
Int J Oncol. 1998 Jul;13(1):57-63.
Int J Oncol. 1998.
PMID: 9625803
Clinical Trial.
Item in Clipboard
Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H.
Kuhn W, et al. Among authors: spathe k.
Cancer. 2001 Nov 15;92(10):2585-91. doi: 10.1002/1097-0142(20011115)92:10<2585::aid-cncr1611>3.0.co;2-#.
Cancer. 2001.
PMID: 11745193
Clinical Trial.
Item in Clipboard
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H.
Kuhn W, et al. Among authors: spathe k.
Br J Cancer. 1999 Apr;79(11-12):1746-51. doi: 10.1038/sj.bjc.6690278.
Br J Cancer. 1999.
PMID: 10206287
Free PMC article.
Item in Clipboard
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W.
Lengyel E, et al. Among authors: spathe k.
Gynecol Oncol. 2001 Aug;82(2):291-8. doi: 10.1006/gyno.2001.6243.
Gynecol Oncol. 2001.
PMID: 11531282
Item in Clipboard
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E.
Schmalfeldt B, et al. Among authors: spathe k.
Clin Cancer Res. 2001 Aug;7(8):2396-404.
Clin Cancer Res. 2001.
PMID: 11489818
Item in Clipboard
Cite
Cite